![logo](/logos/VNDA.webp)
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
5.02 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Vanda Pharmaceuticals Inc. |
Symbool | VNDA |
Munteenheid | USD |
Prijs | 5.02 |
Beurswaarde | 292,614,796 |
Dividendpercentage | 0% |
52-weken bereik | 3.3 - 6.75 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mihael H. Polymeropoulos M.D. |
Website | https://www.vandapharma.com |
An error occurred while fetching data.
Over Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)